NRC Health (NRC) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. NRC Health is a provider of analytics and insights for healthcare organizations, focusing on patient and employee experience. The company operates as a single reporting segment. On February 26, 2025, the Board appointed Trent Green as the new Chief Executive Officer, effective June 1, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $33.6 million | $35.3 million |
| Net Income | $5.8 million | $6.4 million |
| Diluted EPS | $0.25 | $0.27 |
| Operating Income | $8.6 million | $8.8 million |
| Operating Margin | 26% | 25% |
| Cash from Operations | $6.6 million | $12.0 million |
| Cash & Equivalents | $2.5 million | $1.7 million |
| Total Debt (Notes Payable + Revolver) | $65.7 million | $14.3 million |
| Recurring Contract Value (TRCV) | $134.4 million | $139.5 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 5% year-over-year, driven by a $2.1 million drop in recurring revenue from existing clients, partially offset by $0.4 million from new clients.
- Expense Reductions: Direct expenses fell 6% due to workforce reductions and automation implemented in late 2024. SG&A expenses decreased 8% due to lower marketing and legal fees.
- Debt Restructuring: In February 2025, the company entered a new credit agreement, extinguishing prior debt and incurring a $67,000 loss. The company drew down significantly on its new Delayed Draw Term Loan, increasing total debt obligations.
- Cash Flow: Operating cash flow decreased 47% primarily due to working capital changes, including timing of billings, prepaid expenses, and tax payments.
- Share Repurchases: The company repurchased 307,709 shares for approximately $5.0 million, exhausting the 2022 program. A new 1.0 million share authorization was approved in April 2025.
Guidance, Outlook, and Risks
- Executive Compensation Impact: Management expects a one-time charge of approximately $3.6 million in Q2 2025 related to the new CEO's signing bonus, plus quarterly non-cash equity charges. Two other executives received similar arrangements totaling $1.7 million in cash bonuses and quarterly equity charges.
- Capital Expenditures: The company estimates $3.7 million in remaining costs for headquarters renovations in 2025, funded by operating cash flow and borrowings.
- Outlook: Management expects operating income and margins to increase in the near term due to revenue and cost initiatives, excluding the impact of the new executive compensation charges.
- Risks: Key risks include client contract non-renewals, competitive price pressure, and the impact of global conflicts or economic downturns. The company maintains a working capital deficit of $17.4 million but asserts sufficient liquidity via credit facilities.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the Fixed Charge Coverage Ratio (1.10x) and Cash Flow Leverage Ratio (3.50x) given the increased debt load and upcoming executive compensation charges.
- TRCV Trend: Monitor the Recurring Contract Value metric closely; while it improved sequentially in Q1 2025, it remains down 4% year-over-year, indicating potential revenue headwinds.
- Executive Transition: Assess the impact of the leadership change (Trent Green) on strategic direction and the immediate financial impact of the disclosed compensation packages.
- Liquidity Position: Review the reliance on the Revolving Loan and Delayed Draw Term Loan to fund operations, dividends, and share repurchases amidst a working capital deficit.